Claims for Patent: 9,695,244
✉ Email this page to a colleague
Summary for Patent: 9,695,244
Title: | Methods related to denosumab |
Abstract: | The present invention relates to the characterization and production of denosumab. |
Inventor(s): | Robblee; John (Newton, MA), Collins; Brian Edward (Arlington, MA), Kaundinya; Ganesh (Bedford, MA), Bosques; Carlos J. (Arlington, MA) |
Assignee: | Momenta Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 14/403,828 |
Patent Claims: | 1. A method of manufacturing a denosumab drug product, comprising: providing or obtaining a test glycoprotein preparation; acquiring a value for each of a plurality of
denosumab parameters listed in Table 1 for the test glycoprotein preparation, wherein the values for the plurality of denosumab parameters distinguishes denosumab from non-denosumab glycoprotein; and wherein the plurality of denosumab parameters
comprises parameters 1 and 4 listed in Table 1; and processing at least a portion of the test glycoprotein preparation as a denosumab drug product if the values for the plurality of denosumab parameters for the test glycoprotein preparation meet the
corresponding reference criteria shown in Table 1 for the parameters, thereby manufacturing an denosumab drug product, or taking an alternative action if the values for the plurality of denosumab parameters for the test glycoprotein preparation do not
meet the corresponding reference criteria shown in Table 1 for the parameters; wherein the test glycoprotein preparation comprises a recombinant antibody composition including a first polypeptide having the amino acid sequence of SEQ ID NO:1 and a
second polypeptide having the amino acid sequence of SEQ ID NO:2, and wherein the first and second polypeptides together form a recombinant antibody.
2. The method of claim 1, wherein the plurality comprises: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 of the denosumab parameters listed in Table 1. 3. The method of claim 1, wherein the value is directly acquired by performing an analytical test on the test glycoprotein preparation. 4. The method of claim 3, wherein the value is directly acquired using C18 UPLC mass spectrometry. 5. The method of claim 1, wherein the processing step comprises combining the test glycoprotein preparation with an excipient or buffer. 6. The method of claim 1, wherein the processing step comprises one or more of: formulating test glycoprotein preparation; combining the test glycoprotein preparation with a second component; changing the concentration of the recombinant antibody composition in the test glycoprotein preparation; lyophilizing the test glycoprotein preparation; combining a first and a second aliquot of the test glycoprotein preparation to provide a third, larger, aliquot; dividing the test glycoprotein preparation into smaller aliquots; disposing the test glycoprotein preparation into a container; packaging the test glycoprotein preparation; associating a container comprising the test glycoprotein preparation with a label shipping or moving the test glycoprotein preparation to a different location. 7. The method of claim 1, wherein the denosumab drug product is approved under Section 351(k) of the Public Health Service (PHS) Act. 8. The method of claim 1, wherein the denosumab drug product is not approved under biologics license application (BLA) under Section 351(a) of the Public Health Service (PHS) Act. 9. The method of claim 1, wherein the value for at least one denosumab parameter for the test glycoprotein preparation comprises an average of values or a range of values for the parameter for multiple batches or samples of the test glycoprotein preparation. 10. The method of claim 1, wherein the plurality of reference criteria shown in Table 1 are a specification for commercial release. 11. The method of claim 1, wherein the values for a plurality of denosumab parameters are acquired for one or more samples or batches of the test glycoprotein preparation. 12. The method of claim 1, comprising: providing a host cell that is genetically engineered to express the first and second polypeptides, culturing the host cell under conditions that allow the cell to express the first and second polypeptides and form recombinant antibodies, harvesting the recombinant antibodies from the host cell culture to produce the test glycoprotein preparation. 13. The method of claim 1, wherein the plurality of denosumab parameters further comprise parameter numbers 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and/or 15 shown in Table 1. 14. The method of claim 1, wherein the denosumab drug product is an interchangeable version, under Section 351(k) of the Public Health Services (PHS) Act, of a denosumab product approved by the FDA. 15. The method of claim 1, wherein the plurality of the reference criteria is a product acceptance criterion. 16. The method of claim 1, further comprising comparing each of the acquired values of the plurality of denosumab parameters to the corresponding reference criterion shown in Table 1. 17. The method of claim 1, wherein taking an alternative action comprises (a) reprocessing, (b) disposing of, or (c) rendering the test glycoprotein preparation unusable for commercial release by labeling or destroying it. 18. The method of claim 1, wherein the processing step comprises formulating the test glycoprotein preparation. 19. The method of claim 1, wherein the processing step comprises combining the test glycoprotein preparation with a second component. 20. The method of claim 1, wherein the processing step comprises lyophilizing the test glycoprotein preparation. |
Details for Patent 9,695,244
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen, Inc. | PROLIA | denosumab | Injection | 125320 | 06/01/2010 | ⤷ Try a Trial | 2032-06-01 |
Amgen, Inc. | XGEVA | denosumab | Injection | 125320 | 11/18/2010 | ⤷ Try a Trial | 2032-06-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.